Alternative splicing of fibronectin increases expression of the EDA þ isoform of fibronectin (EDA þ Fn), a damageassociated molecular pattern molecule, which promotes fibro-inflammatory disease through the activation of toll-like receptors. Our studies indicate that the fibronectin EDA domain drives two waves of gene expression in human dermal fibroblasts. The first wave, seen at 2 hours, consisted of inflammatory genes, VCAM1, and tumor necrosis factor. The second wave, evaluated at 24 hours, was composed of the fibrosis-associated cytokines IL-10 and IL-13 and extracellular matrix genes fibronectin and osteopontin. Gene expression was coordinately regulated by the a4b1 integrin and the innate immune receptor toll-like receptor 4. Additionally, we found a significant toll-like receptor 4/a4b1-dependent enrichment in the ratio of EDA þ Fn to total fibronectin in response to EDA, consistent with EDA þ Fn initiating further production of EDA þ Fn. Our data also suggest that the EDA/a4b1 integrin interaction primes the cell for an enhanced response to toll-like receptor 4 ligands. Our studies provide evidence that remodeling of the fibronectin matrix in injured or diseased tissue elicits an EDA-dependent fibro-inflammatory response in dermal fibroblasts. The data suggest a paradigm of damage-associated molecular patternebased signaling whereby damage-associated molecular pattern binding integrins cooperate with innate immune receptors to stimulate inflammation and fibrosis.
INTRODUCTION
Plasma fibronectin (pFn) is a soluble plasma protein that is synthesized by liver hepatocytes and assembled into the extracellular matrix (ECM) of most tissues. Structurally, fibronectin is a modular protein whose secondary structure is organized into repeating, independently folded domains (types I, II, and III) based on amino acid sequence homology. Cellular fibronectin can also be synthesized locally by resident tissue fibroblasts and is increased in response to injury and pathological stimuli. Fibroblast-synthesized fibronectin RNA undergoes alternative splicing, which regulates the inclusion or exclusion of an additional type III domain, EDA þ Fn. EDA þ Fn is selectively synthesized and polymerized into ECM by stromal fibroblasts. EDA þ Fn is not detected in normal, resting tissue of the adult but is prominently expressed during development, during wound healing, and in association with various disease processes (Schwarzbauer and DeSimone, 2011; White and Muro, 2011) . The EDA domain of fibronectin is now widely recognized as a damage-associated molecular pattern (DAMP) capable of activating the innate immune receptor, toll-like receptor 4 (TLR4) on both immune and nonimmune cells (Gondokaryono et al., 2007; Kelsh et al., 2014; McFadden et al., 2011; Okamura et al., 2001) . That EDA þ Fn contributes to prolonged inflammation and fibrosis has been documented in several mouse models of fibro-inflammatory disease (Arslan et al., 2011; Booth et al., 2012; Dhanesha et al., 2015; Julier et al., 2015; Khan et al., 2012; Kohan et al., 2011) . Earlier research has highlighted a role for EDA þ Fn and TLR4 in promoting cutaneous inflammation (McFadden et al., 2010 (McFadden et al., , 2011 . More recently, keloid scars were found to have extensive amounts of EDA þ Fn, which can potentially contribute to the increased inflammation and collagen production associated with this disease (Andrews et al., 2015; Kelsh et al., 2015) . EDA þ Fn-dependent TLR4 signaling has been linked to the increased collagen production and myofibroblast differentiation seen in the skin of scleroderma patients. The TLR4 agonist activity of the EDA domain of fibronectin can be seen in the context of the intact molecule, proteolytic fragments, and recombinant peptides (Bhattacharyya et al., 2014; Doddapattar et al., 2015; Gondokaryono et al., 2007; Julier et al., 2015; Mogami et al., 2013) . However, the molecular mechanisms underlying EDA's role in the initiation and persistence of fibrotic and inflammatory processes are not well understood.
Activation of TLR4 by its canonical ligand, lipopolysaccharide, requires the use of co-receptors or ancillary proteins, such as CD14 and MD2, to facilitate TLR4 activation (Park et al., 2009 ). The TLR4 co-receptors that control DAMPinitiated TLR4 activation and signaling are not well understood. Recently, we reported that the interaction between the profibrotic contractile phenotype in dermal fibroblasts that is characterized by an increase in actin stress fibers, myosin light chain phosphorylation, and fibronectin matrix (Shinde et al., 2015) . These findings suggest that the a4b1 integrin may cooperate with innate immune receptors to control fibrotic outcomes in this cell type. In this study we identify the EDA-binding integrin, a4b1, as essential to the TLR4-dependent induction of profibrotic genes by the EDA domain. These data suggest that in dermal fibroblasts, the a4b1 integrin functions as a TLR4 co-receptor to initiate the fibro-inflammatory response to EDA þ Fn.
RESULTS AND DISCUSSION
To assess alterations in fibrotic gene expression in response to EDA, we used real-time reverse transcriptaseePCR (RT-PCR) microarray analysis and evaluated the changes in gene expression at early (2 hours) and late (24 hours) time points. To look at early gene induction, human dermal fibroblasts were seeded onto pFn alone or a mixture of pFn and the EDA domain for 2 hours. RNA was extracted and induced genes detected using both an ECM and adhesion molecular array and a fibrosis array (see Supplementary Tables S1eS4 online) . Several genes were found to be up-regulated by more than 3.0-fold within 2 hours of seeding cells onto substrates coated with pFn and EDA compared with pFn alone (Figure 1a and b). These genes include those for TNF-a, IL-10, IL-1A, VCAN, and VCAM1 (Figure 1c and d) . These genes have all been linked to the regulation of fibrosis and inflammation. At 2 hours, the most highly up-regulated genes after seeding onto EDA were VCAM1 and TNF-a (Figure 1c and d). VCAM1 expression on stromal fibroblasts may have implications for the formation of tertiary lymph organs, which are often seen in chronically inflamed tissue. It has been proposed that fibroblast VCAM1, by serving as the counterreceptor for the leukocyte a4b1 integrin, promotes chronic inflammation by mediating lymphoid/stromal cell binding and preventing the emigration of leukocytes from sites of tissue damage (Buckley et al., 2015) . These lymphoid/stromal cells can organize into structures, termed tertiary lymphoid organs, that promote chronic inflammation (Jones et al., 2016) . TNF-a, a proinflammatory cytokine, has been shown to initiate a pathological cascade that begins with lingering inflammation, ultimately leading to fibrotic disease in multiple organ systems (Duerrschmid et al., 2015; Matsui et al., 2014; Oikonomou et al., 2006) . In addition to TNF-a and VCAM1, there was also an increase in chondroitin sulfate proteoglycan, versican, and the profibrotic cytokines IL-1 and IL-10. Of particular note, versican has been identified as an activator of TLR2-dependent signaling to generate an inflammatory microenvironment , showing its role as an ECM DAMP. Versican's up-regulation in response to EDA suggests a potential feed-forward loop in dermal fibroblasts, driven by ECM DAMPs. Collectively, the upregulation of these genes by EDA suggests an initial, robust profibrotic inflammatory phenotype being evoked in these cells that can further lead to feed-forward fibro-inflammatory events. We found that a different subset of genes became upregulated by EDA at 24 hours (Figure 1e and f) . Several profibrotic cytokines, transforming growth factor (TGF)-b1, IL-10, and IL-13, were found to be up-regulated by EDA (Figure 1g and h) . TGF-b1 regulates fibrosis by promoting myofibroblast differentiation and the increased synthesis of collagen and EDA þ Fn (Bochaton-Piallat et al., 2016) . IL-10 and IL-13 are anti-inflammatory cytokines that have been implicated in Th2-dependent fibrosis (Kaviratne et al., 2004; Sziksz et al., 2015) . The subsequent production of cytokines upon Th2 macrophage polarization can result in the generation of many different ECM-remodeling associated genes: LOX, MMP-2 and -9, and procollageneI and eIII, showing a critical link between the T helper type 2 response and fibrogenesis (Decitre et al., 1998; Kaminski et al., 2000; Underwood et al., 2000; Wang and Hirschberg, 2003) . IL-13 has been shown to indirectly activate latent TGF-b1 by regulating increased amounts of metalloproteases capable of releasing TGF-b1 from the ECM (Lanone et al., 2002; Lee et al., 2001 ). In our study, EDA resulted in increased TGFb1 gene expression at 24 hours, which upon activation by IL-13 could lead to a feed-forward mechanism driving further production of EDA þ Fn (White et al., 2010) . Additionally, EDA induced the expression of the ECM proteins osteopontin and fibronectin. This finding is in agreement with our recent finding that the a4b1-EDA interaction induces an increase in the accumulation of fibronectin matrix in human dermal fibroblasts (Shinde et al., 2015) . Osteopontin is a multifunctional matricellular protein that has been implicated in organ fibrosis (Arriazu et al., 2017; Lancha et al., 2014; Lenga et al., 2008) . Osteopontin has also been linked to myofibroblast differentiation in response to TGF-b, which in dermal and cardiac fibroblasts leads to a dramatic increase in EDA þ Fn and a-smooth muscle actin (Lenga et al., 2008) . The cell adhesion molecule selectin (i.e., SELL) is a counter-receptor for leukocyte selectins and, like VCAM-1, could contribute to the formation of tertiary lymphoid tissue.
We further characterized the kinetics of expression of several of these genes in dermal fibroblasts by real-time RT-PCR over a 24-hour time frame. We found two distinct waves of gene expression: an initial wave of inflammatory genes (i.e., VCAM1, TNF-a) seen at 2 hours ( Figure 2a ) followed by a late-phase wave of fibrotic genes at 24 hours that included the ECM proteins osteopontin and fibronectin, as well as the fibrosis-associated cytokines IL-10 and IL-13 (Figure 2b ). Of particular interest was the up-regulation of fibronectin expression. Inflamed and fibrotic skin is characterized by the increased deposition of the alternatively spliced EDA þ Fn isoform into the ECM (Andrews et al., 2015; Bhattacharyya et al., 2014; Fullard and O'Reilly, 2016; McFadden et al., 2010) . To assess whether EDA could also influence the isoform of fibronectin being synthesized, we used a primer specific to the EDA region of fibronectin or a primer that recognizes all isoforms of fibronectin and performed RT-PCR. We found that although there was no change in the overall expression of fibronectin at 2 hours, there was a change in the relative levels of the EDA þ isoform of fibronectin. At 2 hours, cells seeded onto EDA substrates exhibited an increase in the proportion of fibronectin mRNA containing the EDA domain compared with cells seeded to a control type III (III10n) module of fibronectin (Figure 2c) . A quantitation of three separate experiments showed a significant increase in RM Kelsh-Lasher et al. Induction of Fibrotic Genes by TLR4 and a4b1 the proportion of EDA þ Fn being synthesized, suggesting that seeding cells onto EDA resulted in a rapid change in the alternative splicing of the Fn transcript (Figure 2d ). To evaluate whether the changes in Fn splicing were accompanied by increased matrix deposition of the EDA þ isoform of Fn, cell layers were solubilized and analyzed by Western blot for expression of the EDA þ isoform of Fn using the IST-9 antibody directed at the EDA domain. As shown in Figure 2e , EDA þ Fn was markedly enhanced in cells seeded onto substrates coated with pFn plus EDA.
EDA is a known ligand for the a4b1 integrin receptor and an established agonist for TLR4. To assess the contribution of each of these receptors to EDA-dependent gene induction, cells were pretreated with blocking antibodies to either TLR4 or the a4 subunit of the integrin. We found that the upregulation of both TNF-a and VCAM1 in response to seeding cells onto EDA was significantly inhibited by blocking antibodies to either TLR4 or a4 (Figure 3a and b) . To further assess the role of a4b1 integrin, the a4 subunit was knocked down using siRNA. Western blot analysis indicated that a4 protein levels were unaffected by control, nontargeting small interfering RNA (siRNA), whereas the a4 siRNA markedly decreased a4 protein levels even 24 hours after lifting and replating cells (Figure 3c ). As shown in Figure 3d , control cells treated with nontargeting siRNA exhibited increased levels of the inflammatory mediators, VCAM1 and TNF-a, in response to EDA, which was significantly inhibited under conditions of a4 knockdown. Similarly, a4 knockdown completely prevented the EDA-mediated induction of IL-10 and IL-13 (Figure 3e) . Furthermore, pretreatment of cells with inhibitors to TLR4 (TAK242) and/or NF-kB (Bay 11-782) completely inhibited expression of all Figure 1 . Fibrosis gene expression profiling in response to EDA. Human dermal fibroblasts were seeded onto wells coated with pFn (10 mg/ml) alone or a mixture of pFn (10 mg/ml) and EDA (40 mg/ml) in 0.1% BSA-DMEM for (a-d) 2 hours or (e-h) 24 hours. Expression profiling of genes was performed with (a, e) an ECM and cell adhesion molecule array, as well as (b, f) a fibrosis array. Fold change lines indicate a 3.0-fold change in baseline. (c, d, g, h) The genes for which expression was changed more than 3.0 fold are displayed in the tables. BSA, bovine serum albumin; ECM, extracellular matrix; pFn, plasma fibronectin; TNF, tumor necrosis factor.
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The role of a4b1 and TLR4 in the synthesis of the EDA þ isoform of fibronectin was also investigated. Fibroblasts were pretreated with a control mouse IgG or blocking antibodies to TLR4 and a4b1, either alone or in combination before seeding onto substrates coated with pFn and EDA or pFn and the control III-10n. After 2 hours, there was little change in total fibronectin mRNA levels, consistent with the data shown in Figure 2 ; however, there was a 5-fold increase in EDA Knockdown of the a4 integrin using siRNA and inhibition of TLR4 signaling with the TAK inhibitor each prevented the increase in EDA þ Fn mRNA in response to EDA (Figure 4b ). These data indicate that both the a4b1 integrin and TLR4 regulate alternative splicing of fibronectin in response to EDA.
Our data highlight a previously unreported link between TLR4 and integrin a4b1 in facilitating fibrotic outcomes in response to EDA. Earlier reports have suggested cooperativity between innate immune signaling and integrins. In immune cells, integrins have been shown to both positively and negatively regulate the TLR-dependent production of inflammatory mediators in response to pathogens (Acharya et al., 2016; Gianni et al., 2012; Han et al., 2010; Marre et al., 2010; Yee and Hamerman, 2013 
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DAMP-mediated fibro-inflammatory responses without compromising host defense against pathogens.
Although we could detect a rapid (2-hour) change in the level of TNF-a mRNA when cells were seeded onto pFn and EDA (Figure 2 ), TNF-a protein was not detected in the medium after 5 hours (data not shown). To explore this further, we took advantage of our previous finding that EDA could synergize with a second fibronectin DAMP, III-1c, to enhance cytokine expression in fibroblasts (Kelsh et al., 2014) . III-1c represents a stable intermediate structure in fibronectin, which is predicted to form during force-induced unfolding of fibronectin's III-1 domain (Gao et al., 2003) . Like EDA, III-1c works through TLR4 to activate the NF-kBedependent release of cytokines (TNF-a, IL-8) from human fibroblasts (Kelsh et al., 2014; You et al., 2010) . Therefore, we asked whether cells adherent to EDA were more responsive to III-1c and whether a4b1 was regulating this response. To address this question, III-1c was added to cells adherent to either pFn or pFn and EDA, and TNF-a released into the medium over a 5-hour period was measured by ELISA. Figure 5 shows that when III-1c is added to cells adherent to pFn and EDA, there is a 4-fold increase in TNF-a compared with cells seeded 
onto pFn alone. The EDA-dependent increase in TNF-a release in response to III-1c was significantly inhibited under conditions of a4 knockdown. In contrast, a4 knockdown had no effect on III-1cestimulated synthesis of TNF-a by cells adherent to pFn alone. These results suggest that the a4b1 integrin specifically regulates the EDA dependent synthesis of cytokines by human fibroblasts and further suggests that cells adherent to EDA þ Fn may be primed for a more robust inflammatory response to additional TLR4 ligands.
MATERIALS AND METHODS
Knockdown of the integrin subunit a4 using siRNA
To suppress the expression of the a4 integrin subunit using siRNA, fibroblasts were cultured at 30e40% confluence in complete medium then transfected for 4 days with 25 nmol/L ON-TARGET plussiRNA targeting a4 or a nontargeting control siRNA (Dharmacon, Lafayette, CO). a4 knockdown was confirmed by immunoblotting using a rabbit monoclonal antibody to a4 (D2E1). Antibodies to a4 integrin and glyceraldehyde-3-phosphate dehydrogenase were obtained from Cell Signaling (Danvers, MA).
Gene profiling
Human dermal fibroblasts were grown overnight in complete medium as previously described (You et al., 2010) . Cells were trypsinized and placed in serum-free medium before plating onto different fibronectin substrates (pFn alone or pFn mixed with EDA) (Shinde et al., 2015) . Cells appeared equally adherent and well spread on both substrates. Incubation times and doses of inhibitors are listed in the respective figure legends. The TLR4 (TAK242) and NF-kB (BAY11-7082) inhibitors were purchased from EMD Millipore (Billerica, MA). Blocking antibody to a4 (MAB16983) was from Millipore (Temecula, CA). Blocking antibody to human TLR4 was obtained from R&D Systems (Minneapolis, MN). Subsequently, total RNA was isolated from fibroblasts using RNeasy extraction kit (Qiagen, Valencia, CA). An RT2 First Strand kit (Qiagen) was used to convert 1.5 mg of RNA into cDNA. The cDNA was applied to either an Extracellular Matrix and Cell Adhesion Molecule Array or a Fibrosis Array (Qiagen). A MyiQ cycler system (Bio-Rad Laboratories, Hercules, CA) was used for real-time PCR detection. Gene expression profiling was analyzed using an Excel (Microsoft, Redmond, WA)-based PCR array data analysis template provided by the manufacturer. Relative gene expression was calculated as the difference in fold change upon treatment and normalized against five housekeeping genes using the DDCt method.
Conventional and real-time RT-PCR
Total RNA was isolated from adherent cells and assayed for expression of EDA þ Fn, total Fn, IL-10, IL-13, SPP1, or b-actin by RT-PCR. PCR primers for amplification of EDA þ Fn were designed and synthesized based on primers from Bhattacharyya et al. (2014) . Fn, TNF, VCAM1, SPP1, IL-10, IL-13, and b-actin primers were purchased from SABiosciences (Frederick, MD). Real-time RT-PCR was performed and data analyzed as previously described (You et al., 2010) . Conventional RT-PCR for EDA Products were electrophoresed on a 1.2% Tris/Borate/EDTA gel, and signals were quantified using a Bio-Rad ChemiDoc Imager. ligands. Human dermal fibroblasts were transiently transfected with 10 nmol/ L a4 siRNA or NT siRNA and seeded onto wells coated with pFn (10 mg/ml) or a mixture of pFn (10 mg/ml) and EDA (40 mg/ml). Cells were then treated with III-1c for 5 hours and conditioned medium analyzed for TNF-a protein by ELISA. The data are expressed as picograms of TNF-a synthesized by 10 6 cells over a 5-hour period. Data were analyzed by analysis of variance. ** P < 0.001; * P < 0.05. pFn, plasma fibronectin; siRNA, small interfering RNA; TLR, toll-like receptor; TNF, tumor necrosis factor.
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Preparation of recombinant fibronectin modules
The cDNA for the fibronectin EDA domain and the III-1c domain were inserted into bacterial expression vector pQE-30 in-frame with an N-terminal 6Â His Tag (Qiagen, Inc., Valencia, CA), transformed, and recombinantly expressed and purified as previously described (Kelsh et al., 2014) . The His-tagged recombinant fibronectin type III module, FnIII-10n, was prepared as previously described (Klein et al., 2003) and served as a control.
Immunoblot analysis
Cell layer lysates were prepared and immunoblotted as previously described (Ambesi and McKeown-Longo, 2014) . Antibodies to EDA þ Fn (IST-9; sc-59826) and FAK (A-17; sc-557) were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
Human TNF-a ELISA
Human dermal fibroblasts were cultured and a4 integrin subunit expression suppressed using siRNA as described. Cells were lifted, rinsed once in serum-free media, and seeded onto dishes coated with pFn (10 mg/ml) or a mixture of pFn (10 mg/ml) and EDA (40 mg/ ml) in the presence of 10 mmol/L III-1c for 5 hours. Conditioned medium was concentrated using an Amicon Ultra-4 10K centrifugal filter and analyzed for TNF-a protein expression using a human TNFa ELISA kit (BD Biosciences, San Diego, CA) as directed by the manufacturer.
